ClinicalTrials.gg
CompletedNCT02471118OKINADAUpdated Oct 27, 2021

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)

A Phase 2 interventional study of Adalimumab 40 mg and Placebo in Osteoarthritis, Knee, sponsored by CARE ARTHRITIS LTD.. Completed at 7 sites in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-10-27.

Sponsored by CARE ARTHRITIS LTD. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 41 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.

Enrollment
82nd of 160
62 · median 65
Started
2015
with 13 others
Phase 2
19 of 171
none open now
Registered
67th of 171
by date

Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 82nd largest by enrollment of the 160 interventional ones that give a count, is one of 14 that started in 2015, is one of 19 in phase 2, and was the 67th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Osteoarthritis, Knee with a site in Canada, or all of them as a file.
02

Study summary

This is a Canadian randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy and safety of adalimumab versus placebo when used to treat subjects with a diagnosis of osteoarthritis of the knee, and with clinical features of inflammation, whose pain persists despite receiving maximum tolerated doses of conventional therapy.

Read the detailed description

This is a Canadian randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy and safety of adalimumab versus placebo when used to treat subjects with a diagnosis of osteoarthritis of the knee, and with clinical features of inflammation, whose pain persists despite receiving maximum tolerated doses of conventional therapy. A total of 100 subjects will be entered into the study.

Subjects will be randomized (1:1) at baseline to receive either adalimumab 40 mg every other week or placebo for 16 weeks. The study drug will be self-administered via subcutaneous injection. Efficacy will be assessed at week 16 while the safety of the study drug will be monitored throughout the study. At week 16 all subjects will begin to receive open label adalimumab 40 mg every other week.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Inflammatory Type
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 40 years of age
  2. If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing methods of .
  3. If female and of childbearing potential, serum pregnancy results must be negative at Screening
  4. Has a diagnosis of Osteoarthritis (OA) of the index knee according to American College of Rheumatology (ACR) criteria, including radiological evidence of OA (Kellgren-Lawrence grades 2 or 3).
  5. Subject has had knee pain for at least 1 month prior to the Screening Visit.
  6. Subject has had knee pain that has persisted despite conventional treatment, defined as any one of the following medications taken for at least 1 month in the past:

    • acetaminophen (2- 4 grams per day)
    • therapeutic dose range of an NSAID
    • acetaminophen/codeine combination (i.e. Tylenol No. 2, 3, 4) taken at least 3 times daily.
  7. Has a pain score of ≥ 4 (0-10 NRS) in the index (more symptomatic) knee at Screening and Baseline.
  8. If the subject is taking Analgesic/NSAIDs, then the Analgesic/NSAIDs has been stable for 14 days prior to the Baseline visit.
  9. Has clinical evidence of a knee effusion in the index (more symptomatic) knee at Screening and Baseline.
  10. Able and willing to self-administer SC injections or has available qualified person(s) to administer SC injections.
  11. Has voluntarily signed and dated an approved form prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has a history of an allergic reaction or significant sensitivity to constituents of adalimumab.
  2. Has other bone and articular diseases (antecedents and/or current signs) such as chondrocalcinosis, Paget's disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis, seronegative spondylo-arthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel disease.
  3. Subject has a over 40.
  4. Planned/anticipated surgery of the index knee during the study period.
  5. Already scheduled for any surgery during the time of the study or within 70 days after the end of treatment.
  6. Prior arthroscopic or open surgery of the index knee within 12 months of Baseline.
  7. Has a history of cancer or lymphoproliferative disease other than: Successfully and completely treated cervical dysplasia, with no recurrence within the last five years, Basal or Squamous Cell Carcinoma that has been adequately treated or excised.
  8. Has had prior treatment with intravenous (IV) immunoglobulin or any agent within 30 days or 5 half-lives of the agent from Baseline, whichever is longer.
  9. History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease (e.g. multiple sclerosis).
  10. History of uncontrolled diabetes, unstable ischemic heart disease, active congestive heart failure, (NHYA) III, IV, inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 12 weeks of Screening), or any other condition, which in the opinion of the investigator, would put the patient at risk by participating in the study.
  11. Has concurrent local or systemic infection that would preclude the use of adalimumab.
  12. Has had a persistent or severe infection(s) requiring hospitalization or treatment with IV antibiotics within 30 days, or oral antibiotics within 14 days, prior to Baseline.
  13. History of active tuberculosis or listeriosis, or other infections suggestive of significant or profound , such as Pneumocystis carinii, aspergillosis or other systemic protozoal or fungal infections.
  14. Has latent TB (positive purified protein derivative (PPD) skin test, two-step PPD when applicable, and chest X-ray indicative of TB) or has other risk factors for the activation of latent TB, e.g. previous exposure to TB, and has not initiated TB prophylaxis prior to the first adalimumab treatment.
  15. Will be excluded if the Chest x-ray is found to have changes indicative of old healed tuberculous lesion (e.g. calcified nodule, fibrotic scar, apical or basilar pleural thickening etc.).
  16. Has a positive serology for or that indicates active infection.
  17. Has a history of positive status.
  18. Currently taking or likely to begin anti-retroviral therapy at any time during the course of the study.
  19. Female subject is pregnant or breast-feeding.
  20. Has a history of drug or alcohol abuse in the last year, prior to Screening.
  21. Subject, in the opinion of the principal investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason.

Treatment-Related Exclusion Criteria

  1. Subject has received intra-articular injections of and/or hyaluronate compounds into the index knee within 12 weeks prior to Baseline.
  2. Subjects using injectable corticosteroids for any medical condition (intra-articular/soft tissue injections are allowed, but not in the target knee).
  3. Subjects using indomethacin or oral steroids.
  4. Subjects taking glucosamine and/or chondroitin at screening must discontinue or remain on a stable dose, unmodified if at all possible for the entire duration of the study.
  5. If treatment for osteoarthritis (NSAID) or osteoporosis (bisphosphonates, selective estrogen receptor modulators) is necessary, it will have to be continued, unmodified if at all possible for the entire duration of the study. If the subject does not wish to continue them during the study, they must be stopped 14 days prior to the Baseline visit.
  6. Subjects who have used compounds containing non-approved agents for arthritis or agents claiming to possess disease/structure-modifying properties in the 14 days prior to the Baseline visit (see exception above).
  7. Subjects who require acetaminophen at daily doses > 4000 mg (4 g) on a regular basis.
  8. Subjects who are taking lithium carbonate, phenytoin or anticoagulants (with the exception of aspirin up to a maximum daily dose of 325 mg).
  9. Subjects who use calcitonin.
  10. Subjects who use immunosuppressive drugs. Subjects that are using methotrexate or hydroxychloroquine must withdraw treatment 1 month prior to baseline, to be eligible to enter the study.
  11. Topical analgesics and NSAID's cannot be used on the target knee within the 48 hours before each study visit.
  12. No new physical modalities of treatment can be introduced and subject must maintain normal activity during the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    1st 50 subjects to Enter the Study

    At Baseline, subjects will be randomized (1:1) to receive study drug (Adalimumab or placebo). The study drug will be provided as a subcutaneous injection (pre-filled syringe) either Adalimumab (ADA) 40 mg/0.8 mL,every other week (EOW) or matching placebo for Adalimumab every other week for 16 weeks. Efficacy will be assessed at Week 16 while the safety of the study drug will be monitored throughout the study. At Week 16 all subjects will begin to receive open label ADA 40 mg EOW and will continue to receive open label ADA up to Week 50. An End of Study visit will be done at Week 52. A Telephone Follow-up will be done at Week 62 to review Adverse Events and Concomitant Medications.

    Drug: Adalimumab 40 mg · Drug: Placebo

  • Experimental
    2nd group of 50 subjects

    At Baseline, subjects will be randomized (1:1) to receive either adalimumab 40 mg every other week or placebo for 16 weeks. All subjects will begin to receive open label adalimumab 40 mg every other week from week 16-week 30, with An End of Study visit at Week 32. A Telephone Follow-up will be done at Week 42 to review Adverse Events and Concomitant Medications.

    Drug: Adalimumab 40 mg · Drug: Placebo

Interventions

  • Adalimumab will be self-administered via subcutaneous (SC) injection

    Also known as: Humira

  • DrugPlacebo

    Placebo will be self-administered via subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Primary Endpoint: the percentage of subjects achieving an Osteoarthritis Research Society International/Outcome Measures in Rheumatology Clinical trials (OARSI/OMERACT) response at Week 16

    The primary efficacy outcome measure will be the percentage of subjects achieving an OARSI/OMERACT response at Week 16.

    Time frame: 16 weeks

Secondary outcomes

  1. Secondary endpoint Knee Injury and Osteoarthritis Outcome (KOOS) composite pain score at 16 weeks.

    1. KOOS composite pain score at 16 weeks.

    Time frame: 16 weeks

  2. Secondary endpoint KOOS composite pain 20/50 response rates

    2. KOOS composite pain 20/50 response rates, i.e., the percentages of subjects showing ≥ 20% and ≥ 50% improvements from baseline in KOOS composite pain scores in the index knee at 16 weeks.

    Time frame: 16 weeks

  3. Secondary Endpoint KOOS activities of daily living score

    3. KOOS activities of daily living score at 16 weeks.

    Time frame: 16 Weeks

  4. Secondary Endpoint KOOS symptoms score

    4. KOOS symptoms score at 16 weeks.

    Time frame: 16 weeks

  5. Secondary Endpoint KOOS sport and recreation function score

    5. KOOS sport and recreation function score at 16 weeks.

    Time frame: 16 weeks

  6. Secondary Endpoint KOOS knee-related quality of life score

    6. KOOS knee-related quality of life score at 16 weeks.

    Time frame: 16 weeks

  7. Secondary Endpoint Patient global assessment of disease status score

    7. Patient global assessment of disease status score at 16 weeks.

    Time frame: 16 weeks

  8. Secondary Endpoint Investigator global assessment of disease status score

    8. Investigator global assessment of disease status score at 16 weeks.

    Time frame: 16 Weeks

  9. Secondary Endpoint Physical assessment of Target Joint

    9. Physical assessment of Target Joint at 16 weeks.

    Time frame: 16 weeks

  10. Secondary Endpoint Expanded Target Joint Assessment score

    10. Expanded Target Joint Assessment score at 16 weeks.

    Time frame: 16 weeks

  11. Secondary Endpoint Average weekly consumption of analgesic medications

    11. Average weekly consumption of analgesic medications over 16 weeks.

    Time frame: 16 weeks

07

Study locations

7 sites
  • Division of Rheumatology, University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Western University
    London, Ontario N6A 4V2, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 7W9, Canada
  • A.M.I.R.
    Montréal, Quebec H4A 3T2, Canada
  • GRMO Inc.
    Québec, Quebec G1B3M7, Canada
  • CHUS Hotel-Dieu
    Sherbrooke, Quebec J1H 2E8, Canada
  • Polmed Research Inc.
    Saskatoon, Saskatchewan S7K 0H6, Canada
08

References and documents

Publications

  • 1. National Advisory Council on Aging and Public Health Agency of Canada, Division of Aging and Seniors. Musculoskeletal disorders such as arthritis and osteoporosis [Online]. Available at http://www.naca-ccnta.ca/vignette/vig69_e.htm#69. 2. Malemud CJ. Cytokines as therapeutic targets for osteoarthritis, BioDrugs 2004;18:23- 35. 3. Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis. 4. Pelletier JP, Martel-Pelletier J, Abramson SB.Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44:1237-1247. 5. Felson DT, McLaughlin S, Goggins J, LaValley MP, Gale ME, Totterman S, Li W, Hill C, Gale D: Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003, 139:330-336. 6. Hunter DJ, Zhang Y, Niu J, Goggins J, Amin S, LaValley MP, Guermazi A, Genant H, Gale D, Felson DT: Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006, 54:1529-1535. 7. Kornaat PR, Kloppenburg M, Sharma R, Botha-Scheepers SA, Le Graverand MP, Coene LN, Bloem JL, Watt I: Bone marrow edema-like lesions change in volume in the majority of patients with osteoarthritis; associations with clinical features. Eur Radiol 2007, 17:3073-3078. More references available
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Mar 2021, 72 months.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 72 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2015
First posted
Jun 15, 2015
StartActual
Mar 2015
Primary completionActual
Mar 2021
CompletionActual
Mar 2021
Last update
Oct 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02471118
Lead sponsor
CARE ARTHRITIS LTD.
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Mar 2015
Primary completion
Mar 2021
Completion
Mar 2021
Last update
Oct 27, 2021

Study contacts

Dr. Walter P Maksymowych, MD, FRCPC
study director · CARE ARTHRITIS LTD.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion